August 19, 2019


Via E-Mail

F. Mark Reuter
Keating Muething Kiekamp PLL
One East Fourth Street, Suite 1400
Cincinnati, OH 45202

         Re:   Medpace Holdings, Inc.
               Schedule 14D-9 filed August 8, 2019
               File No. 5-89605

Dear Mr. Reuter:

     The Office of Mergers and Acquisitions has reviewed the filing listed
above. Our
comments follow. All defined terms have the same meaning as in your filing.

       Please respond to this letter by revising your filing, by providing the
requested
information, or by advising us when you will provide the requested response. If
you do not
believe our comments apply to your facts and circumstances or do not believe an
amendment is
appropriate, please tell us why in your response.

       After reviewing any amendment to your filing and the information you
provide in
response to these comments, we may have additional comments.

Schedule 14D-9

Item 4

   1. Please revise to provide further detail about why Medpace Holdings is not
making a
      recommendation to Eligible Option Holders. It is true in the case of any
tender offer that
      whether to participate is based in part on each holder's personal
situation. Please expand
      to explain what specifically about this offer by an affiliate of the
Company informed the
      Board's decision not to make a recommendation to subject security
holders.

   2. See our last comment above. Summarize the deliberations at the meeting
cited in
      subparagraph (b) of this section, including the Board's consideration of
"numerous
      factors" leading up to its determination with respect to the Offer.
 F. Mark Reuter, Esq.
Keating Muething Kiekamp PPL
August 19, 2019
Page 2



General

   3. In your response letter, indicate how you disseminated the Schedule 14D-9
and how you
      intend to disseminate the revisions made in response to comments above.


    We remind you that the filing persons are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.
Please contact me at (202) 551- 3263 with any questions about these comments.

                                                    Sincerely,

                                                    /s/ Christina Chalk

                                                    Christina Chalk
                                                    Senior Special Counsel
                                                    Office of Mergers and
Acquisitions